Skip to content

Released Nov 7, 2019, after the close

10-Q filed Nov 8, 2019, 39 days after period end · 0001564590-19-041909

Q3 2019 · 10-Q
Revenue$12.28M+56.7% vs Q3 2018+16.6% vs Q2 2019
Net Income-$12.91MN/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.56N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$12,735,000N/M
Operating Cash Flowderived-$16,121,000N/M
Free Cash Flowderived-$16,788,000N/M
Margins · derived
Operating margin-103.7%+25.9 pt vs Q3 2018
Net margin-105.2%+25.5 pt vs Q3 2018

What the release said

The release

Same quarter

MetricQ3 2019Q3 2018Q3 2017
Revenue$12.28M$7.84M$17.50M
Net Income-$12.91M-$10.24M-$1.42M
EPS Diluted-$0.56-$21.26-$3.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR